

MAY 06 2004

Substitute for form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/766,122		
				Filing Date	January 27, 2004		
				First Name Inventor	Hoffmann, et al.		
Sheet	1	of	1	Attorney Docket Number	21558 US		
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
KH	A1	5,972,938		Rupniak et al.	10/26/1999		
KH	A2	US 2003/0004157		Buser et al.	01/2003		
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ³
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
KH	B1		WO 95/16679		Merck & Co., Inc.	06/22/1995	
	B2		WO 95/18124		Merck Sharp Dohme Ltd	07/06/1995	
	B3		WO 95/23798		Merck & Co., Inc.	09/08/1995	
	B4		EP 1 035 115 A1		F.Hoffmann-La Roche AG	09/13/2000	
	B5		WO 02/085458		F.Hoffmann-La Roche AG	10/31/2002	
✓	B6		GB 2347422		F.Hoffmann-La Roche AG	09/06/2002	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
KH	C1	Navari, et al., <i>New England J. of Medicine</i> , Vol. 340, pgs. 190-195 (1999)	
	C2	Maggi et al., <i>J. Auton. Pharmacol.</i> , Vol. 13, pgs. 23-93 (1993)	
	C3	Kramer et al., <i>Science</i> , Vol. 281, pgs. 1640-1645 (1998)	
	C4	Longmore et al., <i>Can. J. Physiol. Pharmacol.</i> , Vol. 75, pgs. 612-621 (1997)	
	C5	Barker, <i>Reviews in Neurosciences</i> , Vol. 7, pgs. 187-214 (1996)	
	C6	Quartara et al., <i>Neuropeptides</i> , Vol. 32(1), pgs. 1-49 (1998)	
	C7	Doi et al., <i>Eur. J. of Pharmacology</i> , Vol. 383(3), pgs. 297-303 (1999)	
	C8	Palma et al., <i>Life Sciences</i> , Vol. 67(9), pgs. 985-1001 (2000)	
	C9	Mutra et al., <i>Nature</i> , Vol. 405, pgs. 180-183 (2000)	
	C10	Stout et al., Neurokinin 1 Receptor Antagonists as Potential Antidepressants, <i>Annu. Rev. Pharmacol. Toxicol.</i> Vol. 41, pgs. 877-906 (2001)	
	C11	Rupniak, N., Elucidating the antidepressant actions of substance P (NK ₁ receptor) antagonists, <i>Current Opinion in Investigational Drugs</i> , Vol. 3(2), pgs. 257-261 (2002)	
✓	C12	Humphrey, J., Medicinal Chemistry of Selective Neurokinin-1 Antagonists, <i>Current Topics in Medicinal Chemistry</i> , Vol. 3, pgs. 1423-1435 (2003)	
Examiner Signature		Date Considered <i>[Signature]</i>	8/30/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

141582